Hereditary Angioedema

Human C1 Esterase Inhibitor (C1-INH) in Subjects With Acute Abdominal or Facial Hereditary Angioedema (HAE) Attacks
NCT00168103 | PHASE 2 | INTERVENTIONAL

HAE is a rare disorder characterized by functional C1 esterase inhibitor deficiency. If not treated adequately, the acute attacks of HAE can be life-threatening and may even result in fatalities, especially in case of swelling of the larynx. This clinical Phase 2/Phase 3 study was designed to provide clinically relevant data on dosing, efficacy and safety in subjects with HAE.

Trial Information
36 Sites
126 Participants
Recruiting
6 Years to 65 Years

If interested, contact clinicaltrials@cslbehring.com for more information

CSL Behring respects your privacy. For an explanation of how CSL Behring will use the information you are submitting, please view our Privacy Policy

SUBMIT
Study Site
Granada Hills,California,United States,91344
Study Site
Weston,Florida,United States,33331
Study Site
Atlanta,Georgia,United States,30342
Study Site
Idaho Falls,Idaho,United States,83404
Study Site
Chicago,Illinois,United States,60612
Study Site
Shreveport,Louisiana,United States,71130
Study Site
Boston,Massachusetts,United States,02115
Study Site
Plymouth,Minnesota,United States,55411
Study Site
Omaha,Nebraska,United States,68131
Study Site
Bronx,New York,United States,10461
Study Site
Cincinnati,Ohio,United States,45231
Study Site
Tulsa,Oklahoma,United States,74133
Study Site
Eugene,Oregon,United States,97401
Study Site
Hershey,Pennsylvania,United States,17033
Study Site
Rapid City,South Dakota,United States,57702
Study Site
Dallas,Texas,United States,75230
Study Site
Bellingham,Washington,United States,98225
Study Site
Buenos Aires,Argentina
Study Site
Westmead,Australia
Study Site
Plovdiv,Bulgaria
Study Site
Sofia,Bulgaria
Study Site
Edmonton,Canada
Study Site
Ottawa,Canada
Study Site
Brno,Czech Republic
Study Site
Budapest,Hungary
Study Site
Tel Hashomer,Israel
Study Site
Skopje,Macedonia, The Former Yugoslav Republic of
Study Site
Grodzisk Mazowiecki,Poland
Study Site
Krakow,Poland
Study Site
Tirgu-Mures,Romania
Study Site
Moscow,Russian Federation
Study Site
Moscow,Russian Federation
Study Site
Moscow,Russian Federation
Study Site
Madrid,Spain
Study Site
Goeteborg,Sweden
Study Site
London,United Kingdom

Study Eligibility Criteria

Additional Studies

Additional studies can be found at ClinicalTrials.gov